Available online at www.sciencedirect.com
SCIENCE DIRECT®
Biochemical and Biophysical Research Communications 337 (2005) 133–137
BBRC
www.elsevier.com/locate/ybbrc

A yeast-based assay reveals a functional defect of the Q488H polymorphism in human Hsp90α

Morag J. MacLean, Marc Martínez Llordella, Nathalie Bot, Didier Picard *

Département de Biologie Cellulaire, Université de Genève, Sciences III, 30 Quai Ernest-Ansermet, CH-1211 Genève 4, Switzerland

Received 17 August 2005
Available online 15 September 2005

Abstract

It has been argued that the molecular chaperone Hsp90 guards the organism against genetic variations by stabilizing variant Hsp90 substrate proteins. However, little is known about polymorphisms affecting its own functions. We have followed up on a recent study describing two polymorphisms that alter the amino acid sequences of the two Hsp90 isoforms Hsp90α and Hsp90β. Hsp90 is essential for cell proliferation in the budding yeast *Saccharomyces cerevisiae*, but the human proteins can replace the endogenous ones. In this growth assay, the variant V656M of Hsp90β was indistinguishable from wild-type. In contrast, the Hsp90α variant Q488H, which carries an alteration of a very highly conserved residue, was severely defective for growth compared to wild-type Hsp90α. Hence, the characteristics of this yeast-based system—simplicity, rapidity, low cost—make it ideal for phenotype screening of polymorphisms in *HSP90* and possibly many other human genes.

Keywords: Hsp90; Molecular chaperone; Polymorphism; Human mutation; *Saccharomyces cerevisiae*; Yeast

The ubiquitous molecular chaperone Hsp90 is essential in all eukaryotes. It is abundant at normal physiological temperatures, accounting for approximately 1–2% of total cellular proteins, and further induced by stress to respond to problems in protein folding [1,2]. Hsp90 interacts with a large, diverse but selective set of substrate proteins, including many kinases and transcription factors, influencing their activity and stability. Therefore, Hsp90 along with other molecular chaperones may have a crucial role in responding to disease and ageing [3,4]. The observation that tumour cells are particularly vulnerable to pharmacological inhibition of Hsp90 has led to clinical trials with Hsp90 inhibitors as potential anti-cancer agents [5,6].

Polymorphisms are widespread throughout the genome and can have an impact on complex traits such as susceptibility or resistance to diseases. Some polymorphisms occurring in protein coding regions are not always evident under normal conditions because Hsp90 can buffer against the effects of genetic variation by stabilizing or assisting a variant protein. This buffering allows for the accumulation of cryptic polymorphisms until they become unleashed by a pathological or environmental challenge [4,7,8]. Likewise, a polymorphism of Hsp90 itself could have an impact on many processes such as human diseases and ageing.

Humans, like most species, have two Hsp90 isoforms, Hsp90α and Hsp90β, which are about 85% identical at the protein level. They are encoded by two separate genes, *HSPCA* and *HSPCB*, respectively. While the expression of the two genes is regulated differently, a clear functional difference of the two protein isoforms in human cells has yet to be identified.

As of today, there have only been two studies on polymorphisms in the *HSP90* genes [9,10]. In a survey of samples from 73 Caucasians [9], a total of 29 genetic variants were found, but only 3 could be expected to alter the gene product. One of these results in a frame-shift and encodes a severely truncated product that would be non-functional if stably expressed. The two others lead to amino acid changes, Q488H and V656M in Hsp90α and Hsp90β,

* Corresponding author. Fax: +41 22 379 6928.
E-mail address: picard@cellbio.unige.ch (D. Picard).

0006-291X/$ - see front matter © 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.bbrc.2005.09.025

respectively. In the more recent smaller study [10], the authors could not link Hsp90 polymorphism with varicocele-associated male infertility although they did find three silent changes. In light of the pivotal role of Hsp90 in many cellular processes, it is of great interest to assess the functionality of genetic variations, and notably those that alter the gene product. One way to approach this question is to reintroduce these variant Hsp90 proteins into a biological assay system. This is what we have undertaken here by testing whether these variants can support Hsp90-dependent growth in yeast.

Materials and methods

Plasmids and strain construction. The human *HSP90α* coding sequences were cloned into plasmid pRS313/GPD-PGK (a gift from A. Kralli), a low copy number CEN/ARS yeast expression vector with a *HIS3* marker derived from pRS313 [11], to generate pRS313/Hsp90α, *HSP90β* was expressed from pHCA/hHsp90β [12]. Point mutations G1464C and G1966A (numbering relative to AUG) were generated in *HSP90α* and *HSP90β*, respectively, by site-directed PCR mutagenesis to produce plasmids pRS313/Hsp90α Q488H and pHCA/hHsp90β V656M. The control plasmid pHCA/hsp82 [12] contains the yeast *HSP82* open reading frame.

All genes are under the control of the strong constitutive promoter from the glyceraldehyde-3-phosphate dehydrogenase (GPD) gene. The yeast strain pp30#10 (MATa *trp1-289 leu2-3,112 his3-200 ura3-52 ade2-101^{oc} lys2-801^{am} Δhsc82::KanMX4 Δhsp82::KanMX4*) containing the *HSC82* gene in a 2μ episome with the *URA3* gene [13] was transformed by the lithium acetate/polyethylene glycol method [14].

Cell growth assays. Yeast cells were cultured in minimal SD media (0.67% yeast nitrogen base without amino acids) supplemented with 2% glucose and essential amino acids and nucleotides. Starter cultures were used to inoculate larger volumes and then cells were grown with shaking at 30 °C until mid-logarithmic phase was reached ($OD_{600} = 0.9$). Cells harvested by centrifugation and washed with water were either processed for protein extraction and analysis or for growth assays. For growth assays, cells were serially diluted by steps of 10 and 5 μl of each dilution was spotted onto solid media. These contained 20 g of Bacto-agar per litre and 2% glucose, and were formulated either as minimal SD medium or rich YPD medium (10 g yeast extract, 20 g Bacto-peptone per litre). Where indicated, 5-fluoro-orotic acid (FOA) was added to select for the loss of the episome containing *HSC82*.

Immunoblotting. Cell extracts were prepared as described previously [15]. After quantification with the Bio-Rad Bradford reagent, 40 μg was loaded onto 7.5% SDS–polyacrylamide gels. To confirm that equal amounts of protein had been loaded, proteins were stained with Ponceau S after transfer onto a nitrocellulose membrane before immunostaining. The blot was probed either with chicken antibodies raised against recombinant yeast Hsp82 (used at 1:500 dilution) [15] or with mouse monoclonal antibodies AC88 or H90-10 (gifts from David Toft) used at 1:1000 dilution to recognize human Hsp90α or Hsp90β, respectively.

Results and discussion

In this study, we explored the phenotype of two *HSP90* polymorphisms identified in humans [9] using the budding yeast *Saccharomyces cerevisiae*. Budding and fission yeasts are the only organisms amenable to investigate Hsp90 function in vivo relatively easily because their genomes can easily be manipulated. The essential endogenous *S. cerevisiae* genes encoding Hsp90, *HSC82*, and *HSP82*, can be removed, provided cell viability is maintained by an episomally expressed copy of either gene [16]. This plasmid can be exchanged by another plasmid driving expression of human Hsp90, which complements a double mutant yeast strain at least for cell growth [17–19].

The polymorphism Q488H in human Hsp90α is a non-conservative substitution of a neutral, polar amino acid to a basic residue. Fig. 1 shows a sequence alignment of the portion surrounding this polymorphism (top panel). This glutamine residue is perfectly conserved from *E. coli* to humans and in both yeast Hsp82 and Hsc82. This is in contrast to the polymorphism V656M in Hsp90β, which occurs in the C-terminal dimerization domain [20–23] in a residue that is poorly conserved in evolution and between isoforms within the same species (Fig. 1, lower panel).

Plasmids expressing either a wild-type isoform of human Hsp90 or a polymorphic variant were expressed in yeast.



Fig. 1. Sequence alignment of the polymorphic portions of Hsp90. Amino acid sequences from several Hsp90 sequences were aligned using the sequence alignment program Clustal. The alignments around the Q488H and V656M polymorphic sequences are shown in the top and bottom panels, respectively. Identical residues are boxed in black, conserved substitutions are shaded in grey. The polymorphic residues investigated are indicated with an asterisk. The residue Q488 is conserved amongst all species, while the residue V656 is only semi-conserved. Aligned sequences: human Hsp90α (Accession Nod. NM_005348) and Hsp90β (NM_007355), mouse Hsp90α (NP_034610) and Hsp90β (NP_032328), chicken Hsp90β (NM_206959), zebrafish Hsp90β (AAH65359), *Drosophila* Hsp83 (P02828), *Caenorhabditis elegans* C47E8.5 (CAA99793), plant *Arabidopsis thaliana* Hsp1 (BAA98982), *Schizosaccharomyces pombe* Swo1 (CAB54152), *Saccharomyces cerevisiae* Hsp82 (A73596) and Hsc82 (M26044), *Candida albicans* Hsp90 (CAA56931), and *Escherichia coli* HtpG (BAB33949).